Digital Access

Digital Access
Access nwherald.com from all your digital devices and receive breaking news and updates from around the area.

Home Delivery

Home Delivery
Local news, prep sports, Chicago sports, local and regional entertainment, business, home and lifestyle, food, classified and more! News you use every day! Daily, weekend and Sunday packages.

Text Alerts

Text Alerts
Stay connected to us wherever you are! Get breaking news updates along with other area information sent to you as a text message to your wireless device.

Email Newsletters

Email Newsletters
We'll deliver news & updates to your inbox. Plan your weekend and catch up on the news with our newsletters.
Local Business

Abbott Labs 2Q income falls after AbbVie spinoff

NORTH CHICAGO – Abbott Laboratories Inc. said Wednesday that its net income fell in the second quarter following the spinoff of its branded drug business, but the results beat Wall Street expectations

Abbott said sales of nutrition and diagnostic products improved, making up for lower sales of generic drugs and medical devices. The company spun off its branded drug business into a separate company called AbbVie on Jan. 1. AbbVie sells products including the anti-inflammatory drug Humira.

Abbott said its net income fell to $476 million, or 30 cents per share, from $1.73 billion, or $1.08 per share, a year ago. Excluding one-time charges and last year's AbbVie results, however, its earnings rose to 46 cents per share from 43 cents per share. Analysts surveyed by FactSet expected 44 cents per share.

Revenue grew 3 percent to $5.45 billion from $5.31 billion. Analysts expected $5.52 billion in revenue

Shares of Abbott Laboratories gained 31 cents to $36.01 in late morning trading.

The company said nutrition revenue increased 8 percent to $1.7 billion on greater sales of pediatric products in international markets, and greater sales of adult nutrition products like Ensure. Diagnostics revenue rose 5 percent to $1.14 billion. Generic drug sales fell 2 percent to $1.22 billion and medical device revenue slid 2 percent to $1.36 billion.

Abbott backed its guidance for the full year, saying it expects to earn between $1.98 and $2.04 per share excluding special items. Analysts expect $2.01 per share on average.

Loading more